Roivant Sciences

Roivant Sciences

Yahoo Finance • 19 days ago

Roivant (ROIV): $9 Billion Sales Potential Faces a Commercialization Test

Roivant Sciences Ltd. (NASDAQ:ROIV) may be entering the most important phase of its business, as its pipeline begins to move from clinical development to commercialization. Stifel initiated coverage of Roivant with a Buy rating and a $51... Full story

Yahoo Finance • last month

Company News for Sep 9, 2026

QUALCOMM Incorporated (QCOM) shares rose 3.2% on optimism over its new data center partnership with Amazon Web Services and its AI growth prospects. Roivant Sciences Ltd. (ROIV) shares surged18.8% after positive Phase 2 results for its pu... Full story

Yahoo Finance • last month

Top Midday Gainers

Roivant Sciences (ROIV) shares soared 19% after the company said its Pulmovant unit's phase 2 PHocus PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • last month

Stocks making the biggest moves premarket: Peloton Interactive, Roivant Sciences, Boston Scientific & more

Check out the companies making the biggest moves premarket: Roivant Sciences — Shares rallied 24% after the pharma company said Phase 2 trial results for subsidiary Pulmovant's mosliciguat demonstrated "a clinically meaningful and statisti... Full story

Yahoo Finance • last month

Dr. Gillian Cannon Joins Lindus Therapeutics’ Board as a Non-Executive Director

BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Lindus Therapeutics, a next-generation drug development company advancing a portfolio of in-licensed assets, has announced the appointment of Dr. Gillian Cannon to its board of directors as a non-... Full story

Yahoo Finance • last month

Pfizer-backed Priovant wins FDA approval for lead asset

[Headquarters of US Food and Drug Administration (FDA)] Grandbrothers/iStock Editorial via Getty Images Priovant Therapeutics, a company backed by Pfizer (PFE [https://seekingalpha.com/symbol/PFE]) and Roivant Sciences (ROIV [https://seek... Full story

Yahoo Finance • 2 months ago

Roivant Sciences Ltd (ROIV) (Q1 2026) Earnings Call Highlights: Strategic Advances and Strong ...

This article first appeared on GuruFocus. R&D Expense: Approximately $200 million for the first quarter of fiscal 2026. G&A Expense: Just under $100 million on a non-GAAP adjusted basis, or $166 million on a GAAP basis. Cash Position: Jus... Full story

Yahoo Finance • 2 months ago

Roivant Sciences GAAP EPS of -$0.26 beats by $0.06, revenue of $1.44M misses by $0.9M

* Roivant Sciences press release [https://seekingalpha.com/pr/20609545-roivant-reports-financial-results-for-the-first-quarter-ended-june-30-2026-and-provides] (ROIV [https://seekingalpha.com/symbol/ROIV]): Q1 GAAP EPS of -$0.26 beats by... Full story

Yahoo Finance • 3 months ago

Pfizer, BioNTech face global patent suits from Arbutus, Roivant over COVID vaccine tech

[Gavel on desk] CatLane Arbutus Biopharma (ABUS [https://seekingalpha.com/symbol/ABUS]) and Genevant Sciences, a subsidiary of Roivant Sciences (ROIV [https://seekingalpha.com/symbol/ROIV]), on Thursday announced the filing of three inter... Full story

Yahoo Finance • 3 months ago

Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders

Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce patents protecting their innovative lipid nanoparticle (“LNP”) technology against Pfizer and BioNTech Received approximately $178M from Mo... Full story

Yahoo Finance • 3 months ago

Could Roivant Sciences Be a Multibagger Stock Over the Next 5 Years?

The pharmaceutical industry is massive, worth over $1.7 trillion globally in 2024. So when an up-and-coming player emerges, it can deliver life-changing returns for investors fortunate enough to get in early. Roivant Sciences (NASDAQ: ROIV... Full story

Yahoo Finance • 4 months ago

Guggenheim Remains Bullish on Roivant Sciences Ltd. (ROIV)

Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the best healthcare stocks to buy with highest upside potential. Guggenheim lifted the price target on Roivant Sciences Ltd. (NASDAQ:ROIV) to $36 from $30 on May 26 and maintained a Buy rating... Full story

Yahoo Finance • 5 months ago

Roivant anticipates $950M Moderna payment in July as it outlines 2H 2026 mosliciguat and IMVT-1402 readouts

Earnings Call Insights: Roivant Sciences Ltd. (ROIV) Q4 2025 MANAGEMENT VIEW * CEO Matthew Gline said the quarter included “the preliminary open-label period data from the 1402 study in D2T RA” and a “planned spotlight… on mosliciguat,... Full story

Yahoo Finance • 5 months ago

Roivant (ROIV) Q4 2025 Earnings Transcript

Image source: The Motley Fool. DATE Wednesday, May 20, 2026 at 8 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Matthew GlineUnknown Executive (Mosliciguat program lead) Need a quote from a Motley Fool analyst? Email pr@fool.com... Full story

Yahoo Finance • 5 months ago

Can a New Arthritis Drug Make Immunovant the Next Biotech Star?

Immunovant reports clinically meaningful trial results for its lead drug candidate. That’s good news for Roivant Sciences. Continue Reading... Full story

Yahoo Finance • 5 months ago

These Two Biotech Stocks Rocketed — And One Just Broke Out

Immunovant stock shot to a two-year high Wednesday on "highly compelling" results for its experimental rheumatoid arthritis treatment. Continue Reading... Full story

Yahoo Finance • 5 months ago

2 Biotech Stocks Are Surging Today Thanks to This Arthritis Drug

Immunovant reports clinically meaningful trial results for its lead drug candidate. That’s good news for Roivant Sciences. Continue Reading... Full story

Yahoo Finance • 5 months ago

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update

Roivant Sciences IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant will provi... Full story

Yahoo Finance • 5 months ago

Here are the major earnings before the open Wednesday

Major earnings expected before the bell on Wednesday include: * Target Corporation (TGT [https://seekingalpha.com/symbol/TGT]) * Lowe's Companies (LOW [https://seekingalpha.com/symbol/LOW]) * ZIM Integrated Shipping Services Ltd. (Z... Full story

Yahoo Finance • 5 months ago

Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy?

Key Points Initiated 1,446,375-share position in Beam Therapeutics; estimated trade size $40.13 million (quarterly average price). Quarter-end stake valued at $34.47 million, a net position change reflecting both trading and price movemen... Full story